Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NSAIDs and oral cancer

This article was originally published in The Tan Sheet

Executive Summary

Long-term use of NSAIDs was linked to reduced incidence of oral cancer, but also was associated with increased risk of death from cardiovascular disease, an online study published Oct. 7 by The Lancet finds. The nested case-control study analyzed data from the Norwegian Health Survey database and identified individuals with oral cancer out of the 9,241 participants who had an increased risk for oral cancer due to heavy smoking, Jon Sudbø, MD, Norwegian Radium Hospital, Oslo, Norway, et al., state. Matched controls were chosen from the heavy smokers who did not have cancer. "NSAID use for 15 or more years had the lowest and most highly significant hazard ratio [.30] for oral cancer," Sudbø et al. explain. However, the finding linking increases in death due to cardiovascular disease and long-term NSAID use "highlights the need for a careful risk-benefit analysis when the long-term use of NSAIDs is considered," the authors say...

You may also be interested in...



US FDA Addresses PFAS In Cosmetics, Aiming To Close Data Gaps

Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.

Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions

Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.

Cara Placing Korsuva Hopes On Oral Formulation, Broad Pruritis Label

I.V. Korsuva now has an August FDA action date, which partner Vifor would commercialize in the ESRD dialysis setting while Cara works toward a broad anti-pruritus label for its oral tablet formulation.

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel